- Trials with a EudraCT protocol (1,995)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (390)
1,995 result(s) found for: vaccine.
Displaying page 19 of 100.
| EudraCT Number: 2006-006307-37 | Sponsor Protocol Number: 810601 | Start Date*: 2007-05-15 | |||||||||||
| Sponsor Name:Baxter Innovations GmbH | |||||||||||||
| Full Title: AN OPEN LABEL PHASE III STUDY OF A VERO CELL-DERIVED WHOLE VIRUS H5N1 INFLUENZA VACCINE TO ASSESS THE IMMUNOGENICITY AND SAFETY AND TO INVESTIGATE THE NEED FOR AND TIMING OF A BOOSTER VACCINATION | |||||||||||||
| Medical condition: H5N1 Influenza vaccination in healthy subjects | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-000518-37 | Sponsor Protocol Number: 580299/013 | Start Date*: 2004-08-27 |
| Sponsor Name:GlaxoSmithKline AS | ||
| Full Title: A phase III, double-blind, randomized, controlled study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine administered intramuscularly according t... | ||
| Medical condition: cervical cancer: the study is conducted in healthy female adolescents | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Female | |
| Trial protocol: NO (Completed) ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-016218-26 | Sponsor Protocol Number: V503-007 | Start Date*: 2010-03-15 |
| Sponsor Name:MSD Finland Oy | ||
| Full Title: A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With R... | ||
| Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) Types 6, ... | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: FI (Completed) DE (Completed) BE (Completed) AT (Completed) DK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-004347-30 | Sponsor Protocol Number: 110886 | Start Date*: 2007-11-07 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine co-administered with GlaxoSmithKline Biolog... | ||
| Medical condition: For active immunization of females from the age of 10 years onwards for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities includi... | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Female | |
| Trial protocol: SE (Completed) HU (Completed) DK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-005445-11 | Sponsor Protocol Number: S06-ROT-304 | Start Date*: 2006-12-13 |
| Sponsor Name:Sanofi Pasteur MSD S.N.C. | ||
| Full Title: An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of the concomitant use of a live pentavalent rotavirus vaccine (RotaTeq®) and a meningococcal group C con... | ||
| Medical condition: RotaTeq® is indicated for the active immunisation of infants from age of 6 weeks for prevention of gastroenteritis due to rotavirus infection. NeisVac-C® is indicated for active immunisation of ch... | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: FI (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-000890-21 | Sponsor Protocol Number: B1851190 | Start Date*: 2019-05-21 | |||||||||||
| Sponsor Name:Pfizer Inc | |||||||||||||
| Full Title: A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CHILDREN 6 TO 17 YEARS OF AGE IN INDIA | |||||||||||||
| Medical condition: Active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in children 6 to 17 yea... | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-001223-13 | Sponsor Protocol Number: V58_31 | Start Date*: 2014-12-03 |
| Sponsor Name:Novartis Vaccines and Diagnostics | ||
| Full Title: A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture or in Embryonated Ch... | ||
| Medical condition: Prophylaxis: Influenza | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2007-000752-14 | Sponsor Protocol Number: GRT82 | Start Date*: 2011-04-19 |
| Sponsor Name:Sanofi Pasteur SA | ||
| Full Title: Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route) | ||
| Medical condition: Vaccination of healthy subjects aged 18 to 60 years (i.e. to the day before the 61st birthday) or 61 years or above (from the day of the 61st birthday) on the day of inclusion with one dose of the ... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2017-001607-80 | Sponsor Protocol Number: 112581 | Start Date*: 2017-11-14 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: An open-label primary vaccination study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ Inactivated Poliomyelitis vaccine Poliorix administered as a three-dose primary vacci... | ||
| Medical condition: Healthy volunteers (Poliomyelitis) | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2009-015175-27 | Sponsor Protocol Number: NVI-250 | Start Date*: 2010-02-16 |
| Sponsor Name:Netherlands Vaccine Institute | ||
| Full Title: Immunogenicity and safety of intradermal injection of reduced dose Inactivated Poliovirus vaccine (IPV) with a jet injector in healthy adults | ||
| Medical condition: The vaccine in this healthy volunteer trial is indicated to prevent poliomyelitis. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-000651-14 | Sponsor Protocol Number: CSLCT-NHF-04-99 | Start Date*: 2005-05-27 |
| Sponsor Name:CSL Limited | ||
| Full Title: A Single Site, Open-Label Study to Evaluate the Immunogenicity and Safety of Influenza Vaccine, CSL Limited in Healthy 'Adults' aged >18 to <60 years and in Healthy 'Older Adults' aged >60 years fo... | ||
| Medical condition: The vaccine is indicated for the prophylaxis of influenza | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-001453-32 | Sponsor Protocol Number: V37_07E2 | Start Date*: 2015-04-29 |
| Sponsor Name:Novartis Vaccines and Diagnostics Srl | ||
| Full Title: A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension study in Chinese children after a 2 + 1 dose series of either CRM197- conjugate Haemophilus influenzae type b vaccine or ... | ||
| Medical condition: Meningitis, epiglottitis, pneumonia, arthritis caused by Haemophilus influenzae type b. | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2006-003769-15 | Sponsor Protocol Number: 108656 | Start Date*: 2006-09-06 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase II, controlled, randomized, single centre, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine with various doses of AS03 adjuvant... | ||
| Medical condition: Immunization against influenza in male and female subjects aged 18-59 years old. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-004517-14 | Sponsor Protocol Number: 106252 | Start Date*: 2005-11-14 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: Open study to determine the immunogenicity and reactogenicity of Influsplit SSW 2005/2006 in children from 6 years until 13 years of age | ||
| Medical condition: Immunization against Influenza in healthy children and children with underlying diseases aged between 6 and 13 years | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-010334-21 | Sponsor Protocol Number: Flu002 | Start Date*: 2009-04-17 |
| Sponsor Name:Oxford University | ||
| Full Title: A phase IIa study to assess the safety and efficacy of a new influenza vaccine candidate MVA-NP+M1 in healthy adults. | ||
| Medical condition: Influenza | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-001547-37 | Sponsor Protocol Number: 113552 | Start Date*: 2015-06-11 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A Phase I, double-blind, randomised, placebo controlled study to evaluate the reactogenicity and safety of a single oral dose of GlaxoSmithKline (GSK) Biologicals’ live attenuated liquid human rota... | ||
| Medical condition: Rotavirus gastroenteritis | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2012-004039-21 | Sponsor Protocol Number: 103366 | Start Date*: 2015-05-20 |
| Sponsor Name:GlaxoSmithKline | ||
| Full Title: An open, multicentric, post-marketing surveillance study to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals’ live attenuated oral Human Rotavirus (HRV) vaccine, Rotarix when a... | ||
| Medical condition: Healthy volunteers (Rotarix is indicated for the prevention of gastro-enteritis caused by Rotavirus, G1 and non G1 serotypes (such as G2, G3, G4, G9)) | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2017-000255-50 | Sponsor Protocol Number: 207347 | Start Date*: 2018-03-12 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase III, open-label, mono-centre, follow-up extension study to evaluate the persistence of immune response to GSK Biologicals’ HPV vaccine in healthy Chinese female subjects who received three ... | ||
| Medical condition: Healthy volunteers (to evaluate the persistence of immune response in subjects who received the HPV-16/18 vaccine, seven to eight years after the last dose of vaccination in the primary study) | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2008-000943-33 | Sponsor Protocol Number: GRT83 | Start Date*: 2008-04-23 |
| Sponsor Name:Sanofi Pasteur SA | ||
| Full Title: Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation (Intramuscular Route) | ||
| Medical condition: Vaccination of healthy subjects aged 18 to 60 years (i.e. to the day before the 61st birthday) or 61 years or above (from the day of the 61st birthday) on the day of inclusion with one dose of the ... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-001513-27 | Sponsor Protocol Number: 112065 | Start Date*: 2015-06-10 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: An open-label primary vaccination study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus in... | ||
| Medical condition: Healthy volunteers (Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases). | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
